I'm LongbridgeAI, I can summarize articles.Maxim Group analyst Jason McCarthy initiated coverage of Theriva Biologics (TOVX) with a Buy rating and a $1.00 price target, citing an undervalued oncolytic virus platform. Key drivers include the advancing VCN-01 pancreatic cancer program, specifically the P2a VIRAGE2 study expected to yield data in Q3 2027, which may enhance partnering prospects. The analyst highlights solid financial runway into 2027 and differentiated mechanisms supporting upside potential despite high risk adjustments.
Theriva Biologics, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy from Maxim Group maintained a Buy rating on the stock and has a $1.00 price target.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Jason McCarthy has given his Buy rating due to a combination of factors, including Theriva’s advancing clinical program and solid financial runway into 1Q27. The initiation of the P2a VIRAGE2 study in first-line metastatic pancreatic cancer aims to refine VCN-01 dosing, which could reduce risk for a future Phase 3 trial and enhance partnering prospects, with key data anticipated in 3Q27.
McCarthy also points to prior VIRAGE data showing meaningful improvements in progression-free survival and response duration, supporting a dose–response relationship for VCN-01. Combined with VCN-01’s differentiated mechanism—systemic administration with stromal-degrading PH20 hyaluronidase—and a valuation framework that still implies upside despite high risk adjustments and discount rates, he views TOVX as undervalued versus peers in the active oncolytic virus space.
TOVX’s price has also changed moderately for the past six months – from $0.205 to $0.230, which is a 12.20% increase.